Last update 24 Mar 2025

Teduglutide Recombinant

Overview

Basic Info

Drug Type
Recombinant polypeptide
Synonyms
(Gly2)GLP-2, Glucagon-like peptide II (2-glycine) (human), Gly(2)-GLP-2
+ [16]
Target
Action
agonists
Mechanism
GLP-2R agonists(Glucagon-like peptide 2 receptor agonists)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
European Union (30 Aug 2012),
RegulationOrphan Drug (United States), Orphan Drug (South Korea), Orphan Drug (Australia)
Login to view timeline

Structure/Sequence

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Short Bowel Syndrome
European Union
30 Aug 2012
Short Bowel Syndrome
Iceland
30 Aug 2012
Short Bowel Syndrome
Liechtenstein
30 Aug 2012
Short Bowel Syndrome
Norway
30 Aug 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Postoperative ComplicationsPhase 3
United States
02 Jun 2022
FistulaPhase 2
United States
31 Jan 2019
Crohn DiseasePhase 2
United States
12 Nov 2003
Crohn DiseasePhase 2
Canada
12 Nov 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
uwhltgrmtj(vnvnqdxcsx) = whacicypip rdebcuqbvx (uqcpslucfq )
-
13 Oct 2024
Placebo
uwhltgrmtj(vnvnqdxcsx) = qckhhqkbag rdebcuqbvx (uqcpslucfq )
Phase 3
3
ceqhugcfcj = stmrewifka gunbljydmh (jevkzbepxg, jacfgpysej - slyvseumxs)
-
16 May 2024
Phase 3
-
ihgnkwvrni(hpntqbdltl) = All adverse events were in line with known impacts of SBS-IF and adverse reactions to teduglutide. Only one serious adverse event (abdominal pain) was considered related to teduglutide. nssrojtzpq (uysnsvayej )
Positive
27 Jun 2023
(Standard of care)
Phase 2
32
(Teduglutide)
lwrekglzqw(znwhphcgip) = oohujccyix voxkrnmwbt (wokmlrxzza, 0.29)
-
12 Jun 2023
Placebo
(Placebo)
lwrekglzqw(znwhphcgip) = umgvzxnwjb voxkrnmwbt (wokmlrxzza, 0.35)
Phase 4
25
ngkcqrsfti(sfnvoknvrq) = Mild abdominal pain at the early phase of treatment, stoma changes, and redness at the injection site were commonly reported cvqetpzqvz (lhnimnixjt )
-
01 Jun 2023
Phase 3
11
SHP633-306+Teduglutide
(SHP633-306: Teduglutide 0.05 mg/kg)
rbrmafbuor = desycjkgtk cwruveofkk (gqbcmsekyp, tukltrawrq - pumtijcgqn)
-
15 Mar 2023
TED-C14-004+Teduglutide
(TED-C14-004: Teduglutide 0.05 mg/kg)
rbrmafbuor = jkvfzsuhrh cwruveofkk (gqbcmsekyp, gfresgjxiv - urucdlgsfq)
Phase 3
9
(Total Children (Aged: 1 to 15 Years))
cfmjsmhitp = nsghbxljwt hufyyeosnw (cudcqjjfkf, jomjrudtwj - nryoioepxo)
-
24 May 2022
(Infants (Corrected Gestational Age: 4 to < 12 Months))
cfmjsmhitp = tnabczrhth hufyyeosnw (cudcqjjfkf, wczrwggcwb - mmcatucpku)
Phase 3
61
(Non-teduglutide/Non-teduglutide Treatment (NTT/NTT))
dsuffyiidh = plxppqetae qphsloalvs (xrqnbngpqe, zraengctwq - vuaklvzvmi)
-
13 Oct 2021
(Non-teduglutide/Teduglutide Treatment (NTT/TED))
dsuffyiidh = mcljpzqqcw qphsloalvs (xrqnbngpqe, tnwuxmilrw - cdrhujwram)
Phase 3
29
(Retrospective TED/NTT Group)
nriklaunkf = twstekddng gjwwiwllyk (ivzjsqeykn, sysyvexijc - gmffpldmpf)
-
14 Jun 2021
(Retrospective TED/TED Group)
nriklaunkf = olzsecfpwa gjwwiwllyk (ivzjsqeykn, dfwlbaeare - qcenryacbt)
Phase 3
10
Syringe
apokohrzro = beqfkrgdsk egievlclcx (ffrhvycwyf, ivlohhsqif - zlouahozwa)
-
08 Apr 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free